Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
How HIV/AIDS got its name − the words Americans used for the crisis were steeped in science, stigma and religious language - 2Benin coup thwarted by loyalist troops, president tells nation
- 3The Green Transformation: 5 Feasible Living Practices
- 4What is ‘Auld Lang Syne’? Why we sing this song at midnight on New Year’s Eve.
- 5Figure out How to Function Successfully with Your Auto Collision Legal advisor for the Best Result
- Individual Preparation Administrations to Raise Your Wellness Process
- Game theory explains why reasonable parents make vaccine choices that fuel outbreaks
- Vote in favor of Your Number one BWM Vehicles
- Dental Embed Developments: Upsetting Current Dentistry
- Creative Tech Contraptions That Will Work on Your Life
- Brazilian cardinal orders a popular Catholic priest to go offline following right-wing attacks
- Big Bear glows with big stars | Space photo of the day for Dec. 31, 2025
- Trump awarded 1st FIFA Peace Prize by Gianni Infantino at 2026 World Cup draw
- Flights canceled at 40 U.S. airports: Follow live updates as FAA cuts to air traffic take effect amid government shutdown
